Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells

A. Murumagi; A. Hirasawa; S. Khan; M. Arjama; T. Pellinen; R. Koivisto-Korander; A. Leminen; A. Magi; T. Aittokallio; R. Butzow; O. Kallioniemi

Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells

A. Murumagi, A. Hirasawa, S. Khan, M. Arjama, T. Pellinen, R. Koivisto-Korander, A. Leminen, A. Magi, T. Aittokallio, R. Butzow, O. Kallioniemi

Tutkimustuotos: Artikkelijulkaisu › Konferenssiesitelmän abstrakti › vertaisarvioitu

Alkuperäiskieli	englanti
Lehti	International Journal of Gynecological Cancer
Vuosikerta	26
Sivut	653-653
Sivumäärä	1
ISSN	1048-891X
Tila	Julkaistu - lokak. 2016
OKM-julkaisutyyppi	Ei sovellu

Siteeraa tätä

Murumagi, A., Hirasawa, A., Khan, S., Arjama, M., Pellinen, T., Koivisto-Korander, R., Leminen, A., Magi, A., Aittokallio, T., Butzow, R., & Kallioniemi, O. (2016). Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells. International Journal of Gynecological Cancer, 26, 653-653.

@article{eacfa814eb514645a52aa91eb3ea4aec,

title = "Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells",

author = "A. Murumagi and A. Hirasawa and S. Khan and M. Arjama and T. Pellinen and R. Koivisto-Korander and A. Leminen and A. Magi and T. Aittokallio and R. Butzow and O. Kallioniemi",

year = "2016",

month = oct,

language = "English",

volume = "26",

pages = "653--653",

journal = "International Journal of Gynecological Cancer",

issn = "1048-891X",

publisher = "BMJ Publishing Group Ltd",

}

Murumagi, A, Hirasawa, A, Khan, S , Arjama, M, Pellinen, T, Koivisto-Korander, R, Leminen, A, Magi, A, Aittokallio, T , Butzow, R & Kallioniemi, O 2016, 'Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells', International Journal of Gynecological Cancer, Vuosikerta 26, Sivut 653-653.

Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells. / Murumagi, A.; Hirasawa, A.; Khan, S. et al.
julkaisussa: International Journal of Gynecological Cancer, Vuosikerta 26, 10.2016, s. 653-653.

Tutkimustuotos: Artikkelijulkaisu › Konferenssiesitelmän abstrakti › vertaisarvioitu

TY - JOUR

T1 - Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells

AU - Murumagi, A.

AU - Hirasawa, A.

AU - Khan, S.

AU - Arjama, M.

AU - Pellinen, T.

AU - Koivisto-Korander, R.

AU - Leminen, A.

AU - Magi, A.

AU - Aittokallio, T.

AU - Butzow, R.

AU - Kallioniemi, O.

PY - 2016/10

Y1 - 2016/10

M3 - Meeting Abstract

SN - 1048-891X

VL - 26

SP - 653

EP - 653

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

ER -